Literature DB >> 1129833

Compatibility of common intravenous solutions with CPD blood.

S E Ryden, H A Oberman.   

Abstract

Blood anticoagulated with CPD was mixed with lactated Ringer's solution, 5 per cent aqueous dextrose, 5 per cent dextrose in 0.225 per cent saline, 5 per cent dextrose in 0.9 per cent saline, and 0.9 per cent saline solution in varying concentrations and incubated at room temperature and 37 C. Clots formed in the blood-lactated Ringer's mixture after five minutes at a citrate:calcium molar ratio of 4:1 or lower. Aqueous dextrose-blood mixtures showed immediate clumping with gross hemolysis after 30 minutes incubation. Blood mixed with 5 per cent dextrose and 0.225 per cent saline hemolyzed within ten minutes incubation at 37 C. No hemolysis occurred in blood mixed with 5 per cent dextrose in 0.9 per cent saline or with 0.9 per cent saline. Traces of solutions labeled with Evans blue dye remained in intravenous administration tubing even 30 minutes after a simulated transfusion was begun. Lactated Ringer's solution and 5 per cent dextrose in 0.225 per cent saline should not be administered concurrently with blood. Lactated Ringer's solution may also be harmful when used to start transfusions as it rapidly produces clots when mixed with CPD blood.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1129833     DOI: 10.1046/j.1537-2995.1975.15375160360.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Effects of various arterial infusion solutions on red blood cells in the newborn.

Authors:  J K Jackson; D P Derleth
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

2.  A new model of severe hemorrhagic shock in rats.

Authors:  Thomas Rönn; Sven Lendemans; Herbert de Groot; Frank Petrat
Journal:  Comp Med       Date:  2011-10       Impact factor: 0.982

Review 3.  Perioperative haemotherapy: II. Risks and complications of blood transfusion.

Authors:  E T Crosby
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.